List of Excipients in Branded Drug MAYZENT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	MAYZENT	siponimod	0078-0979	CELLULOSE, MICROCRYSTALLINE	2032-01-05
Novartis Pharmaceuticals Corporation	MAYZENT	siponimod	0078-0979	CROSPOVIDONE	2032-01-05
Novartis Pharmaceuticals Corporation	MAYZENT	siponimod	0078-0979	FERRIC OXIDE RED	2032-01-05
Novartis Pharmaceuticals Corporation	MAYZENT	siponimod	0078-0979	FERROSOFERRIC OXIDE	2032-01-05
Novartis Pharmaceuticals Corporation	MAYZENT	siponimod	0078-0979	GLYCERYL DIBEHENATE	2032-01-05
Novartis Pharmaceuticals Corporation	MAYZENT	siponimod	0078-0979	LACTOSE MONOHYDRATE	2032-01-05
Novartis Pharmaceuticals Corporation	MAYZENT	siponimod	0078-0979	LECITHIN, SOYBEAN	2032-01-05

Mayzent Excipient Strategy and Commercial Opportunities: Formulation, Generic Entry and Patent Risk

Last updated: September 3, 2026

Mayzent (siponimod) is a small-molecule, orally administered sphingosine-1-phosphate receptor modulator marketed by Novartis for adults with relapsing forms of multiple sclerosis and active secondary progressive multiple sclerosis. Its excipient opportunity is concentrated in low-dose tablet uniformity, manufacturing robustness, coating performance, and generic substitution rather than in biologic-style delivery technology. The reference product uses conventional solid oral excipients, leaving potential room for differentiated generic formulations and excipient-supplier partnerships.[1]

What excipients are used in Mayzent tablets?

Mayzent tablets contain a conventional immediate-release tablet core and a film coating. The FDA prescribing information identifies the following inactive ingredients:

Formulation component	Publicly disclosed excipient or material	Commercial relevance
Tablet filler and diluent	Lactose monohydrate	May require lactose-control or lactose-free alternatives
Binder and compressibility aid	Microcrystalline cellulose	Supports tablet hardness and compactability
Disintegrant	Croscarmellose sodium	Controls tablet breakup and dissolution
Glidant	Colloidal silicon dioxide	Improves powder flow and content uniformity
Lubricant	Magnesium stearate	Reduces punch and die friction
Film coating	Polyvinyl alcohol, titanium dioxide, talc, and iron oxide colorants	Supports identification, appearance and coating uniformity

The exact colorant combination can vary by strength. The 0.25 mg and 2 mg tablets have different visual identification characteristics, which is commercially relevant for manufacturing controls and medication-error prevention.[1]

The label does not establish the complete quantitative composition, particle-size distribution, grade selection, granulation process, compression force, coating weight gain, or supplier identity. Those parameters can materially affect bioequivalence, dissolution, manufacturability and supply-chain cost.

Why is the 0.25 mg Mayzent tablet the primary excipient challenge?

The 0.25 mg strength contains a very small quantity of siponimod relative to the total tablet mass. This creates a high content-uniformity burden. The principal technical risks are API segregation, poor blend homogeneity, electrostatic behavior, over-lubrication, tablet-weight variability and sensitivity to the selected excipient grade.

A generic manufacturer must normally control:

1. Siponimod distribution throughout the blend.
2. Assay and content uniformity at the tablet level.
3. Dissolution similarity against the reference product.
4. Stability under temperature and humidity stress.
5. Mechanical integrity during packaging and shipment.
6. Visual differentiation between titration and maintenance strengths.

The 2 mg maintenance tablet is less challenging from a dose-loading perspective, but it remains sensitive to granulation, lubrication and coating conditions. A formulation that performs adequately at 2 mg may not transfer directly to 0.25 mg.

Highest-value excipient technologies

The most commercially attractive technologies are:

• Co-processed filler-binder systems that improve low-dose blend uniformity.
• Spray-dried lactose or engineered lactose grades with predictable flow.
• Mannitol, dibasic calcium phosphate or other lactose-free diluents for differentiated formulations.
• Low-peroxide and low-moisture excipient grades for oxidative and hydrolytic stability.
• Fine-particle colloidal silicon dioxide systems that improve flow without excessive dust.
• Modified croscarmellose grades that provide consistent disintegration across compression forces.
• Ready-to-use film-coating systems with stable iron-oxide dispersion.
• Process analytical technology for blend uniformity and tablet-weight control.

The strongest value proposition is not a generic claim that an excipient is “better.” It is a demonstrated reduction in process variability, batch rejection, dissolution drift or analytical failure.

What formulation opportunities exist for Mayzent generics?

The principal opportunity is a robust, low-dose immediate-release tablet platform that can support both strengths with minimal manufacturing complexity.

Lactose-free Mayzent formulation

A lactose-free formulation could target patients or prescribers seeking avoidance of lactose-containing medicines. Potential replacement systems include mannitol, microcrystalline cellulose, dibasic calcium phosphate or co-processed combinations.

The commercial value depends on whether the substitute maintains:

• Equivalent dissolution across physiological pH conditions.
• Acceptable tablet hardness and friability.
• Comparable stability.
• Reliable siponimod content uniformity at 0.25 mg.
• A viable ANDA or other applicable generic regulatory pathway.

A lactose-free product may support a differentiated product strategy, but the substitution must be assessed against the reference product’s in vivo and in vitro performance. It may also create new intellectual-property opportunities if the formulation uses a defined excipient ratio, particle-size range or manufacturing process.

Co-processed excipient platform

A co-processed excipient could combine a filler, binder and flow aid into a single engineered material. For Mayzent, the main benefit would be improved low-dose API distribution and simpler scale-up.

A patentable platform could focus on:

• A defined ratio of microcrystalline cellulose and mannitol.
• A specified particle-size distribution.
• A controlled moisture range.
• A direct-compression process.
• A defined blend uniformity threshold.
• Performance across both 0.25 mg and 2 mg strengths.

The patent position would be stronger if the excipient system delivers an unexpected technical result, such as improved content uniformity or reduced dissolution variability, rather than merely replacing one conventional filler with another.

Film-coating system

Mayzent’s colored film coating creates a narrower opportunity. A supplier could offer a ready-to-use coating system designed to produce equivalent color, opacity, adhesion and moisture protection with lower coating time or reduced defect rates.

Potential commercial claims include:

• Lower spray rate sensitivity.
• Reduced twinning and picking.
• Improved color uniformity.
• Reduced coating weight.
• Better stability under high humidity.
• Simplified supply of titanium dioxide and iron-oxide pigments.

Color matching is important for a generic product because strength differentiation is part of medication safety. A coating that is technically equivalent but visually too similar across strengths could create regulatory or commercial problems.

What patents protect Mayzent and its formulations?

Mayzent’s principal protection is expected to arise from siponimod composition-of-matter and related pharmaceutical patents, not from the publicly disclosed list of excipients alone. The FDA label identifies ingredients but does not disclose whether Novartis has claimed particular excipient grades, ratios, manufacturing parameters or coating processes.[1]

Patent analysis should separate four categories:

Patent category	Relevance to Mayzent	Risk to an excipient entrant
Siponimod composition of matter	Protects the active ingredient and chemical structure	High for API suppliers and generic manufacturers
Solid-form or polymorph patents	May control the API form used in tablets	High if the selected API form is claimed
Formulation patents	May claim tablet composition, dissolution or stability	Material if claims cover excipient ratios or process parameters
Method-of-use patents	May cover treatment of active secondary progressive MS or patient subgroups	Relevant to labeling and skinny-label strategy

An excipient supplier generally does not infringe a formulation patent merely because its material is used in a Mayzent-like tablet. Risk depends on the patent claims and the customer’s complete product. A supplier can still face inducement or contributory-infringement theories if it actively markets an excipient for use in a claimed formulation.

How strong is the Mayzent patent estate?

The estate is commercially strong if it combines valid composition-of-matter protection with enforceable formulation or method claims. It is weaker for excipient-focused competition when:

• The listed excipients are conventional.
• The formulation claims are narrow.
• The formulation patent depends on a specific quantitative ratio.
• The generic can use a different excipient system.
• The patent does not appear in the FDA Orange Book and cannot support a standard Paragraph IV listing dispute.

The practical conclusion is that excipient suppliers should design around claim language rather than assume that all Mayzent tablet technology is proprietary. Public labeling is insufficient to determine freedom to operate.

When does Mayzent lose exclusivity?

Mayzent received FDA approval on March 26, 2019. Because siponimod was approved as a new chemical entity, the product received five years of FDA marketing exclusivity, subject to the statutory framework governing abbreviated applications and Paragraph IV certifications.[2]

Event	Date or status
FDA approval	March 26, 2019
Five-year NCE exclusivity	Generally through March 26, 2024
Generic application opportunity	Potentially earlier for a Paragraph IV filing, subject to applicable rules
Small-molecule status	Yes
Biosimilar pathway	Not applicable
Orange Book relevance	Applicable if qualifying patents are listed

Patent expiration dates can extend beyond regulatory exclusivity. A generic may file after NCE exclusivity ends but still face patent certification, litigation and launch-risk issues. Patent-term adjustment, patent-term extension, pediatric exclusivity and settlement agreements can change the effective entry date.[2,3]

What is the Orange Book status of Mayzent?

The Orange Book is the controlling FDA source for listed patents and exclusivity associated with approved small-molecule products. Mayzent should be assessed by reviewing:

• The current product listing for siponimod.
• Listed patent numbers and expiration dates.
• Whether each patent is directed to the active ingredient, formulation or method of use.
• The certification deadline associated with each listed patent.
• Any updates to the FDA patent-listing database.

An Orange Book listing does not guarantee patent validity. It determines the certification framework and can trigger a 30-month stay if the patent holder files infringement litigation within the applicable period after receiving a Paragraph IV notice.[3]

Which companies are challenging Mayzent patents?

Publicly identified generic challengers and Paragraph IV litigation should be verified against FDA records and PACER before an investment or licensing decision. A reliable competitive assessment must distinguish:

• ANDA filers that have submitted Paragraph IV certifications.
• Applicants using Paragraph III certifications with delayed entry.
• Companies developing alternative formulations without immediate commercial launch plans.
• Litigation settlements that provide a licensed entry date.
• Authorized-generic or license arrangements involving Novartis.

No biosimilar challenge is relevant because siponimod is a chemically synthesized small molecule, not a biologic. Competitive pressure will come from generic tablets, potential authorized-generic supply and therapeutic substitution within the multiple-sclerosis market.

What generic launch scenarios exist for Mayzent?

Three launch scenarios matter commercially.

Early Paragraph IV launch

A generic applicant challenges listed patents before all relevant patent protection expires. The applicant may receive 180-day first-filer exclusivity if statutory requirements are met. This scenario creates the greatest upside but also the highest litigation cost and launch uncertainty.

Post-patent launch

A generic waits for patent expiry or a non-infringing determination. This reduces litigation risk but allows multiple applicants to enter at once, increasing price erosion.

Licensed or settlement entry

Novartis and a generic applicant agree on an entry date, potentially with supply, licensing or authorized-generic terms. Such agreements can create a defined commercial window but may restrict independent formulation or manufacturing plans.

For an excipient supplier, the second and third scenarios are usually more attractive because customers have clearer production forecasts. The first scenario can create rapid demand but exposes the supplier to formulation redesign, litigation disruption and uncertain launch timing.

How does Mayzent compare with competing multiple-sclerosis drugs?

Mayzent competes with oral, injectable and infusion therapies, including Gilenya (fingolimod), Ocrevus (ocrelizumab), Kesimpta (ofatumumab), Mavenclad (cladribine), Aubagio (teriflunomide) and Tecfidera or generic dimethyl fumarate.

Product	Active ingredient	Dosage platform	Biosimilar risk	Excipient opportunity
Mayzent	Siponimod	Immediate-release tablets	None	High for low-dose uniformity and generic tablets
Gilenya	Fingolimod	Capsules	None	Capsule-fill and generic solid oral systems
Ocrevus	Ocrelizumab	Intravenous biologic	Yes, eventually	Sterile formulation and biologic manufacturing
Kesimpta	Ofatumumab	Subcutaneous biologic	Yes, eventually	Device, injectable and cold-chain systems
Tecfidera	Dimethyl fumarate	Delayed-release capsules	None	Enteric coating and stability systems

Mayzent has a more accessible excipient strategy than injectable biologics because development centers on conventional oral solid dosage technology. Its clinical differentiation in active secondary progressive MS can support continued branded demand, while the tablet platform remains technically reproducible by generic manufacturers.[1,4]

What licensing and commercial opportunities exist for excipient companies?

The most actionable opportunities are commercial supply agreements rather than broad product licensing.

Priority targets

1. Supply engineered filler-binders for the 0.25 mg strength.
2. Provide lactose-free or low-lactose platform formulations.
3. Supply ready-to-use colored coating systems.
4. License analytical methods for blend uniformity and dissolution control.
5. Offer dual-source excipient supply with validated equivalence.
6. Develop packaging systems that reduce moisture exposure and tablet abrasion.
7. Support contract manufacturers with scale-up and process-validation packages.

A supplier with a proprietary co-processed excipient can pursue a formulation-development partnership with an ANDA applicant. The strongest agreement structure would tie payments to formulation selection, bioequivalence success, regulatory approval and commercial volume.

What geographic coverage and manufacturing barriers apply?

The United States is the key market for Orange Book-driven generic competition. Europe, Canada, Japan, Australia and emerging markets apply different patent, data-exclusivity and regulatory rules. A formulation that avoids U.S. listed patents may still encounter European patent claims or national validation issues.

Manufacturing barriers are moderate rather than extreme. The main barriers are:

• Consistent 0.25 mg content uniformity.
• API access and acceptable solid form.
• Validated dissolution similarity.
• Color and coating reproducibility.
• Stability in commercial packaging.
• Regulatory documentation for excipient grade changes.
• Reliable supply of pharmaceutical-grade pigments and functional excipients.

The API and regulatory package are likely to be more significant barriers than the availability of conventional tablet excipients. Excipient differentiation is most valuable when it reduces those downstream risks.

Key Takeaways

• Mayzent uses conventional lactose-based immediate-release tablet technology.
• The 0.25 mg titration strength is the central formulation challenge because of low API loading.
• Co-processed excipients, lactose-free systems and ready-to-use film coatings offer the clearest commercial opportunities.
• Siponimod is a small molecule, so biosimilar competition is irrelevant.
• FDA NCE exclusivity began with the March 26, 2019 approval and generally expired in March 2024.
• Orange Book patents, Paragraph IV certifications and litigation settlements determine practical generic-entry timing.
• Excipient companies should pursue supplier partnerships with generic applicants rather than assume that conventional ingredients themselves create strong patent positions.
• The most defensible excipient IP will claim measurable technical performance, defined composition and a reproducible process.

FAQs about Mayzent excipients and generic competition

Does Mayzent contain lactose?

Yes. The FDA label identifies lactose monohydrate as an inactive ingredient in Mayzent tablets.[1]

Can a generic Mayzent tablet use different excipients?

Yes, provided the applicant satisfies applicable pharmaceutical-equivalence, bioequivalence, quality and labeling requirements. Different excipients can create new formulation, stability or regulatory risks.

Is there a biosimilar version of Mayzent?

No. Siponimod is a chemically synthesized small molecule. Competition would proceed through generic-drug pathways rather than the biosimilar pathway.

What is the best excipient opportunity for the Mayzent 0.25 mg strength?

A co-processed or engineered filler-binder system that improves siponimod content uniformity, flow and compression performance has the strongest technical rationale.

Can an excipient supplier patent a Mayzent-compatible formulation?

Potentially. Patentability depends on novelty, nonobviousness, written description and claim scope. A patent based solely on substituting one routine tablet excipient for another is generally less defensible than a formulation producing a documented, unexpected performance benefit.

References

1. U.S. Food and Drug Administration. (2024). Mayzent (siponimod) prescribing information. Novartis Pharmaceuticals Corporation.
2. U.S. Food and Drug Administration. (n.d.). New chemical entity exclusivity. FDA.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
4. Novartis AG. (2023). Annual report 2023. Novartis.